<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: minimal revenues from", fill: "#ef3038"},
{source: "4: minimal revenues from", target: "4: Befar in Asia ", fill: "#ef3038"},
{source: "4: Befar in Asia ", target: "4: development", fill: "#ef3038"},
{source: "4: development", target: "4: agreements", fill: "#ef3038"},
{source: "4: agreements", target: "4: generated revenues", fill: "#ef3038"},
{source: "4: generated revenues", target: "4: products under development", fill: "#ef3038"},
{source: "4: minimal revenues from", target: "6: generate revenues", fill: "#b57281"},
{source: "6: generate revenues", target: "6: profitability", fill: "#b57281"},
{source: "6: profitability", target: "6: commercialization", fill: "#b57281"},
{source: "6: commercialization", target: "6: products currently under development", fill: "#b57281"},
{source: "6: generate revenues", target: "8: profitable will depend among", fill: "#8b4513"},
{source: "8: profitable will depend among", target: "8: proposed products", fill: "#8b4513"},
{source: "8: proposed products", target: "8: regulatory approvals", fill: "#8b4513"},
{source: "8: regulatory approvals", target: "8: products on", fill: "#8b4513"},
{source: "8: products on", target: "8: timely basis", fill: "#8b4513"},
{source: "8: timely basis", target: "8: licensing manufacturing", fill: "#8b4513"},
{source: "8: licensing manufacturing", target: "8: distributing", fill: "#8b4513"},
{source: "8: profitable will depend among", target: "23: proprietary products under development", fill: "#cd853f"},
{source: "23: proprietary products under development", target: "23: additional", fill: "#cd853f"},
{source: "23: additional", target: "23: significant funds", fill: "#cd853f"},
{source: "23: significant funds", target: "23: inform potential customers", fill: "#cd853f"},
{source: "23: inform potential customers", target: "23: thirdparty", fill: "#cd853f"},
{source: "23: thirdparty", target: "23: distributors", fill: "#cd853f"},
{source: "23: distributors", target: "23: distinctive characteristics", fill: "#cd853f"},
{source: "23: proprietary products under development", target: "28: preclinical studies", fill: "#bdda57"},
{source: "28: preclinical studies", target: "28: clinical trials", fill: "#bdda57"},
{source: "28: clinical trials", target: "28: products must", fill: "#bdda57"},
{source: "28: products must", target: "28: demonstrated", fill: "#bdda57"},
{source: "28: demonstrated", target: "28: effective", fill: "#bdda57"},
{source: "28: effective", target: "28: indicated uses", fill: "#bdda57"},
{source: "28: preclinical studies", target: "37: will depend upon", fill: "#a57164"},
{source: "37: will depend upon", target: "37: Novartis ", fill: "#a57164"},
{source: "37: Novartis ", target: "37: development", fill: "#a57164"},
{source: "37: development", target: "37: manufacturing", fill: "#a57164"},
{source: "37: manufacturing", target: "37: commercialization", fill: "#a57164"},
{source: "37: commercialization", target: "37: regulatory approval", fill: "#a57164"},
{source: "37: will depend upon", target: "73: Currently ", fill: "#ec5800"},
{source: "73: Currently ", target: "73: Common Stock ", fill: "#ec5800"},
{source: "73: Common Stock ", target: "73: Nasdaq National Market", fill: "#ec5800"},
{source: "73: Currently ", target: "89: government", fill: "#a8516e"},
{source: "89: government", target: "89: regulations", fill: "#a8516e"},
{source: "89: government", target: "START_HERE", fill: "#a8516e"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Commercial and Professional Services</td>
    </tr>
    <tr>
      <td>Diversified Commercial Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Household Products</td>
    </tr>
    <tr>
      <td>Personal Products</td>
    </tr>
    <tr>
      <td>Leisure Products</td>
    </tr>
    <tr>
      <td>Paper Products</td>
    </tr>
    <tr>
      <td>Household and Personal Products</td>
    </tr>
    <tr>
      <td>Building Products</td>
    </tr>
    <tr>
      <td>Agricultural Products</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Negotiation</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lundbeck">Lundbeck</a></td>
      <td>Lübeck (German: [ˈlyːbɛk] (listen); Low German also Lübeek), officially the Hanseatic City of Lübeck (German: Hansestadt Lübeck), is a city in Northern Germany. With around 217,000 inhabitants, Lübeck is the second-largest city on the German Baltic coast and in the state of Schleswig-Holstein, after its capital of Kiel, and is the 35th-largest city in Germany.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Marine_Products_Export_Development_Authority">Marine Products Export Development Authority</a></td>
      <td>The Marine Products Export Development Authority (MPEDA) is a Government of India company headquartered at Kochi. It was constituted on 24 August 1972, under the Marine Products Export Development Authority Act 1972 (No.13 of 1972).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tesaro">Tesaro</a></td>
      <td>Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Scrum_(software_development)">Scrum (software development)</a></td>
      <td>Within project management, scrum, sometimes written Scrum or SCRUM, is a framework for developing, delivering, and sustaining products in a complex environment, with an initial emphasis on software development, although it has been used in other fields including research, sales, marketing and advanced technologies. It is designed for teams of ten or fewer members, who break their work into goals that can be completed within time-boxed iterations, called sprints, no longer than one month and most commonly two weeks.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/International_Surrey_Company">International Surrey Company</a></td>
      <td>International Surrey Company Ltd., also called "The Surrey Company", is a quadracycle manufacturer based in La Marque, Texas, United States.  The company began production in the mid-1980s and specializes in providing products for the quadracycle rental market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cellulosic_ethanol">Cellulosic ethanol</a></td>
      <td>Cellulosic ethanol is ethanol (ethyl alcohol) produced from cellulose (the stringy fiber of a plant) rather than from the plant's seeds or fruit. It can be produced from grasses, wood, algae, or other plants.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bioprospecting">Bioprospecting</a></td>
      <td>Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example,  almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gross_domestic_product">Gross domestic product</a></td>
      <td>Gross domestic product (GDP) is a monetary measure of the market value of all the final goods and services produced in a specific time period by countries. GDP (nominal) per capita does not, however, reflect differences in the cost of living and the inflation rates of the countries; therefore, using a basis of GDP per capita at purchasing power parity (PPP) may be more useful when comparing living standards between nations, while nominal GDP is more useful comparing national economies on the international market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_relationship_management">Customer relationship management</a></td>
      <td>Customer relationship management (CRM) is a process in which a business or other organization administers its interactions with customers, typically using data analysis to study large amounts of information.CRM systems compile data from a range of different communication channels, including a company's website, telephone, email, live chat, marketing materials and more recently, social media. They allow businesses to learn more about their target audiences and how to best cater for their needs, thus retaining customers and driving sales growth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Papanasam_(film)">Papanasam (film)</a></td>
      <td>Papanasam (transl. Destruction of Sins) is a 2015 Indian Tamil-language crime drama film directed by Jeethu Joseph, a remake of his 2013 Malayalam film Drishyam, which starred Mohanlal. The film was jointly produced by Suresh Balaje and Rajkumar Sethupathi.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ISA_230_Documentation">ISA 230 Documentation</a></td>
      <td>ISA 230 Audit Documentation is one of the International Standards on Auditing. It serves to direct the documentation of audit working papers in order to assist the audit planning and performance; the supervision and review of the audit work; and the recording of audit evidence resulting from the audit work in order to support the auditor's opinion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Physical_inventory">Physical inventory</a></td>
      <td>Physical inventory is a process where a business physically counts its entire inventory.  A physical inventory may be mandated by financial accounting rules or the tax regulations to place an accurate value on the inventory, or the business may need to count inventory so component parts or raw materials can be restocked.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Warehouse">Warehouse</a></td>
      <td>A warehouse is a building for storing goods. Warehouses are used by manufacturers, importers, exporters, wholesalers, transport businesses, customs, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Northern_Fleet">Northern Fleet</a></td>
      <td>The Northern Fleet (Russian: Северный флот, Severnyy flot) is the fleet of the Russian Navy in the Arctic.According to the Russian ministry of defence: "The Northern Fleet dates its history back to a squadron created in 1733 to protect the territories of the Russian Empire, sea trade routes and fisheries in the White Sea near the coast of the Kola Peninsula. The order of the Commander-in-Chief of the Russian Navy of 25 May 2014 determined 1733 as the year of foundation of the Northern Fleet, and June 1 as its annual holiday".In its modern iteration, the Arctic Ocean Flotilla of the former Imperial Navy evolved into a full fleet of the Soviet Navy in 1933 as the Northern Flotilla.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_software">Proprietary software</a></td>
      <td>Proprietary software, also known as non-free software or closed-source software, is computer software for which the software's publisher or another person reserves some licensing rights to use, modify, share modifications, or share the software, restricting user freedom with the software they lease. It is the opposite of open-source or free software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government">Government</a></td>
      <td>A government is the system or group of people governing an organized community, generally a state.\nIn the case of its broad associative definition, government normally consists of legislature, executive, and judiciary.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_agency">Government agency</a></td>
      <td>A government or state agency, sometimes an appointed commission, is a permanent or semi-permanent organization in the machinery of government that is responsible for the oversight and administration of specific functions, such as an administration. There is a notable variety of agency types.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Our  current  business  <font color="blue"><font color="blue">operations</font> began</font> in 1994 and we have a limited     operating history</td>
    </tr>
    <tr>
      <td>We may encounter delays, uncertainties and <font color="blue">complications</font>     typically encountered by <font color="blue">development</font> stage businesses</td>
    </tr>
    <tr>
      <td>We have generated     <font color="blue">minimal revenues from</font> the limited sales of Befar^® in Asia and research and     <font color="blue">development</font> <font color="blue"><font color="blue">agreement</font>s</font> and have received an initial dlra4 million payment from     Novartis, but have not marketed or <font color="blue">generated revenues</font> in the US from our     products under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We are not profitable and have incurred an     <font color="blue">accumulated deficit</font> of dlra117cmam687cmam621 since our inception and through <font color="blue"><font color="blue">December </font>    </font>31, 2005</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">generate revenues</font> and to achieve <font color="blue">profitability</font> and     positive  cash  flow  will  depend  on  the  successful  licensing  or     <font color="blue">commercialization</font> of our <font color="blue">products currently</font> under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>However, even     if we eventually <font color="blue">generate revenues</font> from sales of our <font color="blue">products currently</font>     under <font color="blue">development</font> or <font color="blue">from licensing fees</font>, we expect to <font color="blue">incur <font color="blue">significant</font></font>     operating  losses  over  the <font color="blue">next <font color="blue">several years</font></font></td>
    </tr>
    <tr>
      <td>Our ability to become     profitable will depend, among other things, on our (1) <font color="blue">development</font> of our     <font color="blue">proposed products</font>, (2) obtaining of <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> of our proposed     <font color="blue">products on</font> a <font color="blue">timely basis</font> and (3) success in licensing, <font color="blue">manufacturing</font>,     <font color="blue">distributing</font> and marketing our <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue"><font color="blue">in<font color="blue">dependent</font></font> registered public <font color="blue">accounting firm</font></font> has doubt as to our     ability to <font color="blue">continue as</font> a going concern</td>
    </tr>
    <tr>
      <td>As a result of our losses to date, expected losses in the future, limited     <font color="blue">capital resources</font> and <font color="blue">accumulated deficit</font>, our <font color="blue">in<font color="blue">dependent</font></font> registered public     <font color="blue">accounting firm</font> has concluded that there is substantial doubt as to our     ability to <font color="blue">continue as</font> a going concern, and <font color="blue">accordingly</font>, our <font color="blue">in<font color="blue">dependent</font></font>     registered public <font color="blue">accounting firm</font> has modified their report on our <font color="blue"><font color="blue">December </font>    </font>31, 2005 consolidated financial statements included in this annual report on     Form 10-K in the form of an <font color="blue">explanatory paragraph describing</font> the events that     have  given  rise  to this <font color="blue">uncertainty</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">factors may</font> make it more     <font color="blue">difficult</font> for us to obtain <font color="blue"><font color="blue">additional</font> funding</font> to meet our <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">continuation</font> is <font color="blue"><font color="blue">dependent</font> upon</font> our ability to generate or obtain sufficient     cash to meet our <font color="blue">obligations</font> on a <font color="blue">timely basis</font> and ultimately to attain     profitable  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  anticipate that we <font color="blue">will continue</font> to incur     <font color="blue">significant</font> losses at least until successful <font color="blue">commercialization</font> of one or     more of our products, and we may never operate profitably in the future</td>
    </tr>
    <tr>
      <td>We will need partnering <font color="blue"><font color="blue">agreement</font>s</font> and <font color="blue"><font color="blue">significant</font> funding</font> to <font color="blue">continue with</font>     our research and <font color="blue">development</font> efforts, and they may not be available</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> expenses for the years ended <font color="blue">December </font>31, 2005,     2004, 2003 were dlra11cmam222cmam099, dlra10cmam684cmam477 and dlra8cmam439cmam340, respectively</td>
    </tr>
    <tr>
      <td>Since     January  1,  1994,  when  we  <font color="blue">repositioned</font>  <font color="blue">ourselves as</font> a medical and     <font color="blue"><font color="blue">pharmaceutical</font> <font color="blue">technology</font> company</font>, and <font color="blue">from such date through</font> <font color="blue">December </font>31,     2005  we have spent dlra81cmam041cmam264 on research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Given our     <font color="blue">current level</font> of <font color="blue">cash reserves</font> and low rate of <font color="blue">revenue generation</font>, we will     not be able to <font color="blue">fully advance</font> our products under <font color="blue">development</font> unless we enter     into <font color="blue">additional</font> partnering <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>If we are successful in <font color="blue">entering into</font>     <font color="blue">additional</font> partnering <font color="blue"><font color="blue">agreement</font>s</font> for our products under <font color="blue">development</font>, we may     receive milestone payments, which will offset some of our research and     <font color="blue">development</font> expenses</td>
    </tr>
    <tr>
      <td>6       _________________________________________________________________       We  will  also  need <font color="blue"><font color="blue">significant</font> funding</font> to pursue our <font color="blue">overall product</font>     <font color="blue">development</font> plans</td>
    </tr>
    <tr>
      <td>In general, products we plan to develop will require     <font color="blue">significant</font> time-consuming and <font color="blue">costly research</font> and <font color="blue">development</font>, clinical     testing, <font color="blue"><font color="blue">regulatory</font> approval</font> and <font color="blue"><font color="blue">significant</font> <font color="blue">investment</font> prior</font> to their     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Even with funding, research and <font color="blue">development</font> activities     may not be successful; our products may not prove to be safe and <font color="blue">effective</font>;     clinical <font color="blue">development</font> work may not be completed; and the anticipated products     may not be <font color="blue">commercially viable</font> or <font color="blue"><font color="blue">successfully</font> marketed</font></td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">no sales force</font> or marketing organization and will need,     but may not be able, to <font color="blue">attract <font color="blue">marketing partners</font></font> or <font color="blue">afford qualified</font> or     experienced marketing and <font color="blue">sales personnel</font></td>
    </tr>
    <tr>
      <td>In order to market our <font color="blue">proprietary</font> products under <font color="blue">development</font>, we will need     to  attract  <font color="blue">additional</font>  marketing  partner(s) that will need to spend     <font color="blue"><font color="blue">significant</font> funds</font> to <font color="blue">inform potential customers</font>, including third-party     <font color="blue">distributors</font>,  of  the <font color="blue">distinctive characteristics</font> and benefits of our     products</td>
    </tr>
    <tr>
      <td>Our operating results and long term success will depend, among     other things, on our ability to establish (1) successful <font color="blue">arrangements</font> with     domestic and <font color="blue">additional</font> <font color="blue">international</font> <font color="blue">distributors</font> and <font color="blue">marketing partners</font>     and  (2) an <font color="blue">effective</font> internal marketing organization</td>
    </tr>
    <tr>
      <td><font color="blue">Consummation </font>of     partnering <font color="blue">arrangements</font> is subject to the <font color="blue">negotiation</font> of <font color="blue">complex contractual</font>     <font color="blue">relationships</font>, and we may not be able to negotiate such <font color="blue"><font color="blue">agreement</font>s</font> on a     <font color="blue">timely basis</font>, if at all, or on terms acceptable to us</td>
    </tr>
    <tr>
      <td>Pre-clinical and <font color="blue"><font color="blue">clinical trial</font>s</font> are <font color="blue">inherently</font> unpredictable</td>
    </tr>
    <tr>
      <td>If we or our     partners do not <font color="blue"><font color="blue">successfully</font> conduct</font> these trials, we or our <font color="blue">partners may</font> be     unable to market our products</td>
    </tr>
    <tr>
      <td>Through pre-clinical studies and <font color="blue"><font color="blue">clinical trial</font>s</font>, our <font color="blue">products must</font> be     <font color="blue"><font color="blue">demonstrate</font>d</font> to be safe and <font color="blue">effective</font> for their <font color="blue">indicated uses</font></td>
    </tr>
    <tr>
      <td>Results from     pre-clinical studies and early <font color="blue"><font color="blue">clinical trial</font>s</font> may not allow for prediction     of  results  in  later-stage  testing</td>
    </tr>
    <tr>
      <td>Future <font color="blue"><font color="blue">clinical trial</font>s</font> may not     <font color="blue">demonstrate</font> the safety and <font color="blue">effective</font>ness of our products or may not result     in <font color="blue"><font color="blue">regulatory</font> approval</font> to market our products</td>
    </tr>
    <tr>
      <td><font color="blue">Commercial </font>sales in the     <font color="blue">United States </font>of our products cannot begin until final FDA approval is     received</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> Novartis to realize the potential of NM100060, and, if we     <font color="blue">successfully</font> enter into similar licensing <font color="blue"><font color="blue">agreement</font>s</font> for other products, we     <font color="blue">will similarly</font> be <font color="blue"><font color="blue">dependent</font> upon</font> our other partners</td>
    </tr>
    <tr>
      <td><font color="blue">In September </font>2005, we announced a <font color="blue">global licensing <font color="blue">agreement</font> with</font> Novartis,     pursuant  to which Novartis acquired the <font color="blue">exclusive worldwide rights</font> to     NM100060, our topical anti-fungal nail treatment product, and agreed to pay     us  up  to  dlra51 million on the <font color="blue">achievement</font> of specific <font color="blue">development</font> and     <font color="blue"><font color="blue">regulatory</font> milestones</font> and assume all costs and <font color="blue">responsibilities</font> related to     NM100060</td>
    </tr>
    <tr>
      <td>In addition, Novartis agreed to <font color="blue">pay us royalties based upon</font> the     level of sales achieved</td>
    </tr>
    <tr>
      <td>In order to realize the full potential of NM100060, we <font color="blue">will depend upon</font>     <font color="blue">Novartis  </font>for  the <font color="blue">development</font>, <font color="blue">manufacturing</font> and <font color="blue">commercialization</font> of     NM100060 and for obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> of NM100060</td>
    </tr>
    <tr>
      <td>In addition,     many of the <font color="blue">milestones upon which</font> the Company would receive payment are     based  upon  the  <font color="blue">satisfaction</font>  of  criteria  set  by Novartis and the     <font color="blue">determination by</font> Novartis to seek <font color="blue"><font color="blue">regulatory</font> approval</font> for the drug</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Novartis  </font>   </font>may  terminate  the  licensing  <font color="blue">agreement</font>,  in  its  entirety  or on a     country-by-country basis, by providing the Company up to 180 days notice</td>
    </tr>
    <tr>
      <td>However, in such case Novartis would be obligated to complete the first     <font color="blue">Phase III </font><font color="blue">clinical trial</font> for the product and the rights to NM100060 would     revert  back  to  NexMed</td>
    </tr>
    <tr>
      <td>Since we intend to pursue similar licensing     <font color="blue">arrangements</font> for other products, we <font color="blue">will similarly</font> be <font color="blue"><font color="blue">dependent</font> on</font> our     partners to realize the full potential of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>Patents and <font color="blue">intellectual</font> property rights are important to us but could be     challenged</td>
    </tr>
    <tr>
      <td><font color="blue">Proprietary  </font>protection for our <font color="blue"><font color="blue">pharmaceutical</font> products</font> is of material     importance to our business in the US and most other countries</td>
    </tr>
    <tr>
      <td>We have     sought and <font color="blue">will continue</font> to <font color="blue">seek <font color="blue">proprietary</font> protection</font> for our products to     attempt  to prevent others from commercializing equivalent products in     <font color="blue">substantially less</font> time and <font color="blue">at substantially lower expense</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success may</font>     <font color="blue">depend on</font> our ability to (1) obtain <font color="blue">effective</font> <font color="blue">patent protection</font> within the     US and <font color="blue"><font color="blue">international</font>ly</font> for our <font color="blue">proprietary</font> <font color="blue">technologies</font> and products, (2)     defend patents we own, (3) preserve our trade secrets, and (4) operate     without infringing upon the <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>In addition, we     have agreed to indemnify our partners for <font color="blue">certain liabilities with respect</font>     to the defense, protection and/or validity of our patents and would also be     required  to  <font color="blue">incur costs</font> or <font color="blue">forego revenue</font> if it is <font color="blue">necessary</font> for our     partners  to  acquire <font color="blue">third party patent licenses</font> in order for them to     exercise the licenses acquired from us</td>
    </tr>
    <tr>
      <td>7       _________________________________________________________________       We have twelve US <font color="blue">patents either</font> acquired or received out of a series of     <font color="blue">patent <font color="blue">applications</font></font> that we have filed in <font color="blue">connection with</font> our NexACT^®     <font color="blue">technology</font> and our NexACT-based products under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>To further     strengthen our <font color="blue">global patent position on</font> our <font color="blue">proprietary</font> products under     <font color="blue">development</font>, and to expand the <font color="blue">patent protection</font> to other markets, we have     <font color="blue">filed under</font> the Patent Cooperation Treaty, <font color="blue">corresponding <font color="blue">international</font></font>     <font color="blue">applications</font>  for  our  issued  US  patents  and pending US patent     <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>While we have obtained patents and have several <font color="blue">patent <font color="blue">applications</font></font> pending,     the extent of <font color="blue">effective</font> <font color="blue">patent protection</font> in the US and other countries is     highly  uncertain and <font color="blue">involves complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>No     <font color="blue">consistent policy addresses</font> the breadth of claims allowed in or the degree     of  protection  afforded  under  patents of medical and <font color="blue">pharmaceutical</font>     companies</td>
    </tr>
    <tr>
      <td>Patents we currently own or may obtain might not be <font color="blue">sufficiently</font>     broad to <font color="blue">protect us against <font color="blue">competitors</font> with</font> similar <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Any of our     patents could be invalidated or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>While we believe that our <font color="blue">patents would prevail</font> in any <font color="blue">potential litigation</font>,     the holders of <font color="blue">competing patents could</font> determine to commence a lawsuit     <font color="blue">against us</font> and <font color="blue">even prevail</font> in any <font color="blue">such lawsuit</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>could result in     substantial  cost to and diversion of effort by us, which may harm our     business</td>
    </tr>
    <tr>
      <td>In addition, our efforts to protect or defend our <font color="blue">proprietary</font>     rights  may  not  be  successful or, even if successful, may result in     substantial cost to us</td>
    </tr>
    <tr>
      <td>We and our licensees depend upon third party <font color="blue">manufacturers</font> for chemical     <font color="blue">manufacturing</font> supplies</td>
    </tr>
    <tr>
      <td>We and our licensees are <font color="blue"><font color="blue">dependent</font> on</font> third party chemical <font color="blue">manufacturers</font> for     the active drugs in our NexACT^®-based products under <font color="blue">development</font>, and for     the supply of our NexACT^® <font color="blue">enhancers</font> that are essential in the <font color="blue">formulation</font>     and production of our topical <font color="blue">products on</font> a <font color="blue">timely basis</font> and at satisfactory     <font color="blue">quality levels</font></td>
    </tr>
    <tr>
      <td>If our validated third party chemical <font color="blue">manufacturers</font> fail to     produce quality <font color="blue">products on</font> time and in <font color="blue">sufficient quantities</font>, our results     would suffer, as we or our <font color="blue">licensees would encounter costs</font> and delays in     <font color="blue">revalidating new third party suppliers</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face severe <font color="blue">competition</font></font></td>
    </tr>
    <tr>
      <td>We are engaged in a <font color="blue">highly competitive industry</font></td>
    </tr>
    <tr>
      <td>We and our licensees can     expect <font color="blue">competition</font> from numerous companies, including large <font color="blue">international</font>     <font color="blue">enterprises</font>, and others entering the industry with regard to our products</td>
    </tr>
    <tr>
      <td>Most  of  these  companies  have  greater  research  and  <font color="blue">development</font>,     <font color="blue">manufacturing</font>, marketing, financial, <font color="blue">technological</font>, personnel and managerial     resources</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font>of competing companies by large <font color="blue">pharmaceutical</font> or     healthcare companies could further enhance such <font color="blue">competitors</font> &amp;apos  financial,     marketing and other resources</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may complete <font color="blue"><font color="blue">clinical trial</font>s</font>,     obtain <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> and <font color="blue">commence commercial sales</font> of their products     before  we  could  enjoy a <font color="blue"><font color="blue">significant</font> competitive advantage</font></td>
    </tr>
    <tr>
      <td><font color="blue">Products     </font>developed by our <font color="blue">competitors</font> may be more <font color="blue">effective</font> than our products</td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">potential product liability</font> and other claims, creating     risks and expense</td>
    </tr>
    <tr>
      <td>We are <font color="blue">also exposed</font> to <font color="blue">potential product liability</font> risks inherent in the     <font color="blue">development</font>, testing, <font color="blue">manufacturing</font>, marketing and sale of <font color="blue">human therapeutic</font>     products</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability insurance</font> for the <font color="blue">pharmaceutical</font> industry is     extremely  expensive,  <font color="blue">difficult</font> to obtain and may not be <font color="blue">available on</font>     acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">liability insurance</font> to cover     claims related to our products that may arise from <font color="blue"><font color="blue">clinical trial</font>s</font>, with     coverage of dlra1 million for any one claim and coverage of dlra3 million in     total, but we do not maintain product <font color="blue">liability insurance</font> and we may need to     acquire <font color="blue">such insurance coverage prior</font> to the <font color="blue">commercial introduction</font> of our     products</td>
    </tr>
    <tr>
      <td>If we obtain <font color="blue">such coverage</font>, we have no guarantee that the coverage     limits of <font color="blue">such insurance policies will</font> be adequate</td>
    </tr>
    <tr>
      <td>A successful claim     <font color="blue">against us</font> if we are uninsured, or which is in excess of our insurance     coverage, if any, could have a material adverse effect upon us and on our     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our stock may be <font color="blue">delisted from</font> Nasdaq, which may make it more <font color="blue">difficult</font> for     you to sell your shares</td>
    </tr>
    <tr>
      <td>Currently, our <font color="blue"><font color="blue">Common Stock</font> </font>trades on the <font color="blue">Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>NASD     <font color="blue">Marketplace Rule </font>4450 provides that a <font color="blue">company must <font color="blue">comply with</font> continuing</font>     listing criteria to maintain its Nasdaq listing</td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>30, 2005, the     Company was <font color="blue">notified by</font> The Nasdaq Stock Market (“Nasdaq”) that for the     previous 10 <font color="blue">consecutive</font> trading days the <font color="blue">market value</font> of the Company’s     Common  Stock  had  been below the minimum dlra50cmam000cmam000 requirement for     continued  inclusion  by  Marketplace  Rule 4450(b)(1)(A)</td>
    </tr>
    <tr>
      <td>Pursuant to     <font color="blue">Marketplace Rule </font>4450(e)(4), the Company was provided 30 calendar days, or     until January 30, 2006, to <font color="blue">regain compliance</font></td>
    </tr>
    <tr>
      <td>In addition, the Company did     not <font color="blue">comply with</font> the <font color="blue">alternative <font color="blue">continued listing criteria</font> provided</font> in     Marketplace  Rule 4450(b)(1)(B), which requires total assets and total     revenue of dlra50cmam000cmam000 each for the <font color="blue">most recently</font> completed <font color="blue">fiscal year</font> or     two of the last three <font color="blue">most recently</font> completed <font color="blue">fiscal year</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">On February </font>6,     2006, the Company received a <font color="blue">letter from</font> the <font color="blue">Nasdaq Hearings Department     </font>stating that it has <font color="blue"><font color="blue">demonstrate</font>d</font> full compliance with <font color="blue">requirements</font> <font color="blue">necessary</font>     for <font color="blue">continued listing on</font> the <font color="blue">Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>8       _________________________________________________________________       In addition, included in Nasdaq’s <font color="blue">continued listing criteria</font> is a minimum     bid  price  per  share of dlra1dtta00</td>
    </tr>
    <tr>
      <td>Failure to maintain such price for 30     <font color="blue">consecutive</font>  days  and beyond a grace period of 180 days could lead to     delisting from the <font color="blue">Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>If we were to be <font color="blue">delisted from</font> the <font color="blue">Nasdaq National Market</font>, our <font color="blue"><font color="blue">Common Stock</font> </font>    would  be listed on the <font color="blue">Nasdaq SmallCap </font>Market, assuming we meet those     <font color="blue">listing <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>If we failed to meet the <font color="blue">Nasdaq SmallCap </font>listing     <font color="blue">requirements</font>, our <font color="blue">stock would</font> be considered a <font color="blue">penny stock under <font color="blue">regulations</font></font>     of the <font color="blue">Securities and Exchange Commission </font>and would therefore be subject to     rules that impose <font color="blue">additional</font> sales practice <font color="blue">requirements</font> on broker-dealers     who sell our securities</td>
    </tr>
    <tr>
      <td>The <font color="blue">additional</font> burdens imposed upon broker-dealers     by  these  <font color="blue">requirements</font> could discourage broker-dealers from effecting     <font color="blue">transactions</font> in our <font color="blue">Common Stock</font>, <font color="blue">which could severely limit</font> the market     liquidity of the <font color="blue"><font color="blue">Common Stock</font> </font>and your ability to sell our securities in the     <font color="blue">secondary market</font></td>
    </tr>
    <tr>
      <td>In addition, if we fail to maintain our listing on <font color="blue">Nasdaq     </font>or any other <font color="blue">United States </font>securities exchange, quotation system, market or     over-the-counter bulletin board, we will be subject to <font color="blue">cash penalties under</font>     investor  rights <font color="blue"><font color="blue">agreement</font>s</font> to which we are a <font color="blue">party until</font> a listing is     obtained</td>
    </tr>
    <tr>
      <td>INDUSTRY RISKS       We are vulnerable to <font color="blue">volatile market <font color="blue">conditions</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">market price</font>s</font> for securities of bio<font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     companies, including ours, have <font color="blue">been highly volatile</font></td>
    </tr>
    <tr>
      <td>The market has from     time to time experienced <font color="blue"><font color="blue">significant</font> price</font> and <font color="blue">volume fluctuations</font> that are     unrelated to the operating performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>In addition,     future announcements, such as the results of testing and <font color="blue"><font color="blue">clinical trial</font>s</font>,     the  status  of  our  <font color="blue">relationships</font>  with  third-party  <font color="blue">collaborators</font>,     <font color="blue">technological</font>  <font color="blue">innovations</font>  or  new therapeutic products, <font color="blue">government</font>al     regulation, <font color="blue">development</font>s in patent or other <font color="blue">proprietary</font> rights, litigation     or public concern as to the safety of products developed by us or others and     general  market  <font color="blue">conditions</font>,  <font color="blue">concerning</font>  us, our <font color="blue">competitors</font> or other     bio<font color="blue">pharmaceutical</font> companies, may have a <font color="blue">significant</font> effect on the market     price of our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>We  and  our  licensees are subject to numerous and complex <font color="blue">government</font>     <font color="blue">regulations</font> which could result in delay and expense</td>
    </tr>
    <tr>
      <td><font color="blue">Governmental </font><font color="blue">authorities</font> in the US and other <font color="blue">countries heavily regulate</font>     the testing, manufacture, labeling, distribution, advertising and marketing     of our <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>None of our <font color="blue">proprietary</font> products under <font color="blue">development</font>     has been approved for marketing <font color="blue">in the US Before </font>any products we develop     are marketed, FDA and comparable foreign agency approval must be obtained     through an extensive clinical study and <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">studies involved</font> in the <font color="blue">approval process</font> are conducted in <font color="blue">three phases</font></td>
    </tr>
    <tr>
      <td>In Phase 1 studies, researchers assess safety or the <font color="blue">most common acute</font>     <font color="blue">adverse effects</font> of a drug and examine the size of doses that patients can     take <font color="blue">safely without</font> a <font color="blue">high incidence</font> of side effects</td>
    </tr>
    <tr>
      <td>Generally, 20 to 100     <font color="blue">healthy volunteers</font> or patients are studied <font color="blue">in the Phase </font>1 study for a period     of <font color="blue">several months</font></td>
    </tr>
    <tr>
      <td>In Phase 2 studies, researchers determine the drugapstas     efficacy with short-term safety by administering the drug to subjects who     have the condition the drug is intended to treat, assess whether the drug     <font color="blue">favorably affects</font> the condition, and begin to identify the correct dosage     level</td>
    </tr>
    <tr>
      <td>Up to several hundred subjects may be studied <font color="blue">in the Phase </font>2 study     for approximately 6 to 12 months, depending on the type of <font color="blue">product tested</font></td>
    </tr>
    <tr>
      <td>Several hundred to thousands of <font color="blue">patients may</font> be <font color="blue">studied during</font> the     Phase  3 studies for a period of from 12 months to <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td><font color="blue">Upon     </font><font color="blue">completion</font> of Phase 3 studies, a <font color="blue">New Drug Application </font>is submitted to the     FDA or foreign <font color="blue">government</font>al <font color="blue">regulatory</font> authority for review and approval</td>
    </tr>
    <tr>
      <td>9       _________________________________________________________________       The failure to obtain requisite <font color="blue">government</font>al approvals for our products     under <font color="blue">development</font> in a <font color="blue">timely manner</font> or at all would delay or <font color="blue">preclude us</font>     and our <font color="blue">licensees from marketing</font> our products or limit the <font color="blue">commercial use</font> of     our products, which <font color="blue">could adversely affect</font> our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Because we intend that our <font color="blue">products will</font> be sold and <font color="blue">marketed outside</font> the     US,  we  and/or  our <font color="blue">licensees will</font> be subject to foreign <font color="blue">regulatory</font>     <font color="blue">requirements</font> governing the conduct of <font color="blue"><font color="blue">clinical trial</font>s</font>, product licensing,     pricing and <font color="blue"><font color="blue">reimbursement</font>s</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">requirements</font> vary widely from country to     country</td>
    </tr>
    <tr>
      <td>The failure to meet each foreign countryapstas <font color="blue">requirements</font> could delay     the introduction of our <font color="blue">proposed products</font> in the <font color="blue">respective foreign country</font>     and  limit our <font color="blue">revenues from sales</font> of our <font color="blue">proposed products</font> in foreign     markets</td>
    </tr>
    <tr>
      <td><font color="blue">Successful </font><font color="blue">commercialization</font> of our products may <font color="blue">depend on</font> the <font color="blue">availability</font>     of <font color="blue">reimbursement</font> to the consumer from third-party healthcare payers, such as     <font color="blue">government</font> and <font color="blue">private insurance</font> plans</td>
    </tr>
    <tr>
      <td>Even if one or more products is     <font color="blue">successfully</font>  brought to market, <font color="blue">reimbursement</font> to <font color="blue">consumers may</font> not be     available or sufficient to allow the <font color="blue">realization</font> of an <font color="blue">appropriate return on</font>     our  <font color="blue">investment</font>  in  product  <font color="blue">development</font> or to sell our <font color="blue">products on</font> a     <font color="blue">competitive basis</font></td>
    </tr>
    <tr>
      <td>In addition, in certain <font color="blue">foreign markets</font>, pricing or     <font color="blue">profitability</font> of prescription <font color="blue">pharmaceutical</font>s is subject to <font color="blue">government</font>al     controls</td>
    </tr>
    <tr>
      <td>In the US, federal and state agencies have proposed similar     <font color="blue">government</font>al  control  and  the  US Congress has recently considered     <font color="blue">legislative</font> and <font color="blue">regulatory</font> reforms that <font color="blue">may affect companies</font> engaged in the     <font color="blue">healthcare industry</font></td>
    </tr>
    <tr>
      <td>Pricing <font color="blue">constraints on</font> our products in <font color="blue">foreign markets</font>     and possibly in the US <font color="blue">could adversely affect</font> our business and limit our     revenues</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OWNING OUR COMMON STOCK       We do not expect to <font color="blue">pay <font color="blue">dividends on</font></font> our <font color="blue">common stock</font> in the foreseeable     future</td>
    </tr>
    <tr>
      <td>Although our <font color="blue"><font color="blue">shareholders</font> may</font> receive dividends, if and when declared by our     board of <font color="blue">directors</font>, we do not intend to declare <font color="blue">dividends on</font> our Common     Stock in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Therefore, you should not purchase our     <font color="blue"><font color="blue">Common Stock</font> </font>if you need immediate or <font color="blue">future income by</font> way of <font color="blue">dividends from</font>     your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We may issue <font color="blue">additional</font> shares of our <font color="blue">capital stock</font> that <font color="blue">could dilute</font> the     value of your shares of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We  are  authorized  to issue 130cmam000cmam000 shares of our <font color="blue">capital stock</font>,     consisting of 120cmam000cmam000 shares of our <font color="blue"><font color="blue">Common Stock</font> </font>and 10cmam000cmam000 shares     of our preferred stock of which 1cmam000cmam000 are designated as <font color="blue">Series A </font>Junior     Participating Preferred Stock, 800 are designated as <font color="blue">Series B </font>8prca Cumulative     Convertible Preferred Stock and 600 are designated as <font color="blue">Series C </font>6prca Cumulative     Convertible Preferred Stock</td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>6, 2006, 65cmam046cmam658 shares of our     <font color="blue"><font color="blue">Common Stock</font> </font>were issued and outstanding and 21cmam978cmam306 shares of our Common     Stock were <font color="blue">issuable upon</font> the exercise or <font color="blue">conversion</font> of <font color="blue">outstanding preferred</font>     stock,  options,  warrants, or other convertible securities (including     preferred stock, warrants and convertible notes held <font color="blue">by certain selling</font>     <font color="blue">shareholders</font>)</td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>6, 2006, there were no shares of <font color="blue">Series A </font>or     <font color="blue">Series B </font>Preferred Stock outstanding and 87dtta5 shares of <font color="blue">Series C </font>Preferred     Stock outstanding</td>
    </tr>
    <tr>
      <td>In light of our need for <font color="blue">additional</font> financing, we may     <font color="blue">issue authorized</font> and <font color="blue">unissued shares</font> of <font color="blue"><font color="blue">Common Stock</font> </font>at below <font color="blue">current market</font>     prices or <font color="blue">additional</font> convertible securities that <font color="blue">could dilute</font> the earnings     per share and book value of your shares of our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">provisions providing</font> for <font color="blue">proportionate <font color="blue">adjustment</font>s</font> in the     event of stock splits, stock dividends, reverse stock splits and similar     events,  certain warrants, as well as our outstanding Preferred Stock,     provide (with certain exceptions) for an <font color="blue">adjustment</font> of the <font color="blue">exercise price</font> if     we <font color="blue">issue shares</font> of <font color="blue"><font color="blue">Common Stock</font> </font><font color="blue">at prices lower than</font> the <font color="blue">then exercise</font> or     <font color="blue">conversion</font> price or the <font color="blue"><font color="blue">then prevailing</font> <font color="blue">market price</font></font></td>
    </tr>
    <tr>
      <td>This means that if we     need to <font color="blue">raise equity financing at</font> a time when the <font color="blue">market price</font> for our     <font color="blue"><font color="blue">Common Stock</font> </font>is lower than the exercise or <font color="blue">conversion</font> price, or if we need     to provide a <font color="blue">new equity investor with</font> a <font color="blue">discount from</font> the <font color="blue">then prevailing</font>     <font color="blue">market price</font>, then the exercise or <font color="blue">conversion</font> price will be reduced and the     dilution to <font color="blue">shareholders</font> increased</td>
    </tr>
  </tbody>
</table>